newsfilter
← Earnings
Earnings Releases·

Elite Pharmaceuticals, Inc. — Second Quarter Fiscal Year 2027 Earnings Summary

  • Consolidated revenues reached $40.1 million, a 10.4% year-over-year increase driven by higher sales of the Elite label amphetamine and naltrexone product lines.
  • Income from operations rose 21% to $9.9 million, while net income attributable to common shareholders totaled $17.3 million for the quarter.
  • No changes to future guidance, strategic initiatives, M&A activity, or capital-return programs were disclosed in the summary.
Company
ELITE PHARMACEUTICALS INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic